NY-THE-ROHATYN-GROUP
13.7.2022 14:02:12 CEST | Business Wire | Press release
The Rohatyn Group (“TRG”), a global asset management firm, today announced that it has completed the acquisition of electric bicycles (“e-bikes”) producer Leader 96 EOOD (“Leader” or the “Company”), from KJK Capital (“KJK”), establishing a partnership with Dimitar Zlatanov, the Company’s CEO and member of the founding family. TRG’s ownership can allow Leader to rapidly accelerate its e-bike production and broaden its product offering to address burgeoning demand from customers across Europe. Terms of the transaction were not disclosed.
Founded in 1996 in Plovdiv, Bulgaria, Leader is a leading producer of e-bikes in Europe with sales across the continent. The Company produces a broad range of e-bikes including touring, trekking, mountain, folding and gravel bike models. The Company is planning to launch a new e-cargo bike in 2023.
“Leader is a highly attractive business that provides a unique and high-quality product offering in the European e-bike sector. The Company is well-positioned to benefit from the continuing transformation of city transport infrastructures towards bicycle-friendly zones, increased demand for practical eco-friendly transportation and shared bike programs, as well as the growth of last-mile micro-delivery. Additionally, an increasing focus on healthier lifestyles means e-bikes can offer a highly democratic exercise solution across a wide spectrum of age and fitness levels,” said TRG’s Colin Clark, Partner and Head of EMEA Private Markets, and Stepan Karpukhin, Managing Director, who led the deal alongside Stanislav Bachvarov, Director.
“Leader is a high-growth business with an international profile that fits in perfectly with TRG’s global approach. We strongly believe that the Company has the potential to be a leading player in the e-bike sector thanks to its focus on customer service and forward-thinking approach to technology,” added Nick Rohatyn, CEO of TRG. “We believe increased adoption of e-bikes can contribute to societal progress towards more sustainable urban development, reduction of carbon emissions, and healthier lifestyles, and are proud to invest in a company that recognizes the significance of a positive environmental impact. We look forward to delivering strong growth alongside Dimitar and his team.”
Dimitar Zlatanov, CEO and member of the founding family, commented, “I am tremendously proud of the growth Leader has already achieved, as we have transformed our business into a leading e-bike producer in Europe. We look forward to continuing our growth in partnership with The Rohatyn Group and leveraging the team’s expertise.”
Kustaa Aima, Managing Partner at KJK Capital added “Leader is a great company that transformed through our period of ownership into a leading European e-bike producer. We wish both TRG and Dimitar Zlatanov all the best and look forward hearing more about the Company’s strong growth in the years ahead.”
About TRG
Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets, headquartered in New York, with a global presence in 16 cities across the US, Latin America, Europe, the Middle East, India and Southeast Asia. For more information, please visit www.rohatyngroup.com
About KJK
Founded in 2010, KJK Capital is an independent, partner owned, private equity manager focused on European Frontier markets with a combined assets under management of EUR 600 million. With main offices in Helsinki, Vilnius and Luxembourg, KJK has also local representation in Estonia, Slovenia, Croatia, Bulgaria and Romania. For more information about KJK, please visit www.kjkcapital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom